| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.069 | 0.04 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.04 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |